Trelegy contains three active ingredients used to treat chronic obstructive pulmonary disease (COPD): fluticasone furoate, umeclidinium, and vilanterol [1]. Fluticasone furoate is an inhaled corticosteroid (ICS), umeclidinium is a long-acting muscarinic antagonist (LAMA), and vilanterol is a long-acting beta2-agonist (LABA) [1][2].
Why are these three ingredients combined in Trelegy?
The combination of fluticasone furoate, umeclidinium, and vilanterol in Trelegy addresses COPD through multiple mechanisms. Fluticasone furoate reduces airway inflammation, a key component of COPD. Umeclidinium relaxes the muscles around the airways, making it easier to breathe. Vilanterol works by relaxing the muscles in the airways and widening them [1]. This triple combination therapy aims to provide comprehensive symptom relief and reduce the frequency of COPD exacerbations [2].
How does Trelegy work?
Trelegy works by targeting different pathways involved in COPD pathophysiology. The inhaled corticosteroid component, fluticasone furoate, suppresses inflammatory cells and mediators in the airways, thereby reducing swelling and mucus production [1]. Umeclidinium, the LAMA, blocks the action of acetylcholine on muscarinic receptors in the smooth muscles of the airways. This blockade prevents bronchoconstriction and leads to bronchodilation [1]. Vilanterol, the LABA, stimulates beta2-adrenergic receptors in bronchial smooth muscle, leading to relaxation and further bronchodilation [1]. Together, these actions improve airflow and reduce breathlessness [2].
What is the difference between Trelegy and other COPD inhalers?
Trelegy is a triple-combination inhaler, meaning it contains three different medications in a single device. Many other COPD inhalers are dual-combination (containing two active ingredients) or single-ingredient medications. Dual inhalers typically combine an ICS with a LABA or a LAMA with a LABA. Single-ingredient inhalers contain either an ICS, LAMA, or LABA. Trelegy offers a more comprehensive treatment option for patients with severe COPD who may not achieve adequate symptom control with dual therapy [2].
When does Trelegy patent expiry occur?
Information regarding the specific patent expiry dates for Trelegy (fluticasone furoate/umeclidinium/vilanterol) is available through specialized patent tracking services. DrugPatentWatch.com tracks patent information for numerous pharmaceutical products, including Trelegy [3].
Who makes Trelegy?
Trelegy is manufactured by GlaxoSmithKline (GSK) [1].
What are the side effects of Trelegy?
Common side effects associated with Trelegy can include pneumonia, increased risk of fractures, and cataracts [1]. Patients using Trelegy should be aware of the potential for adverse events such as oral candidiasis (thrush), hoarseness, and throat irritation [1]. Serious side effects, though less common, can include paradoxical bronchospasm, cardiovascular effects, and hypersensitivity reactions [1].
Can I switch to Trelegy from another COPD medication?
Switching to Trelegy may be considered for patients with COPD who require additional treatment beyond dual therapy. Decisions about medication changes should be made in consultation with a healthcare provider who can assess the individual patient's condition, symptom severity, and response to previous treatments [2].
---
Sources
1. "Trelegy Ellipta". RxList. https://www.rxlist.com/trelegy-ellipta-drug.htm
2. "Trelegy for COPD: Uses, Side Effects, Dosage, and More". Medical News Today. https://www.medicalnewstoday.com/articles/trelegy-for-copd
3. DrugPatentWatch.com. https://drugpatentwatch.com/